We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarker Identifies Septic Patients at Higher Risk for Mortality

By LabMedica International staff writers
Posted on 28 Jan 2020
Print article
Image: Blood smear of patient with intracellular cocci in pairs inside a white blood cell, possibly indicating sepsis. Oncostatin-M is a biomarker for sepsis risk (Photo courtesy of Dr. Wim van der Meer).
Image: Blood smear of patient with intracellular cocci in pairs inside a white blood cell, possibly indicating sepsis. Oncostatin-M is a biomarker for sepsis risk (Photo courtesy of Dr. Wim van der Meer).
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion.

Oncostatin-M (OSM) is a pleiotropic cytokine of the interleukin-6 (IL-6) family. OSM secretion has been associated with the modulation of multiple inflammatory diseases, including rheumatoid arthritis, asthma, inflammatory bowel disease, osteoarthritis, hepatic cellular carcinoma and bacterial pneumonia. However, the role of OSM in sepsis has remained unclear.
Laboratory scientists at the Chongqing Medical University (Chongqing, China) enrolled 49 patients with sepsis at the Second Affiliated Hospital of the university intensive care unit (ICU) between October 2017 and December 2018 and analyzed serum OSM levels on their day of admission. The effects of OSM on polymicrobial sepsis induced by cecal ligation and puncture (CLP) were assessed.

The team reported that results of the study showed that on day 1 of ICU admission, septic patients had higher serum OSM levels compared with ICU patient controls and healthy volunteers. Further, they found that a high serum OSM level at ICU admission was independently predictive of 28-day mortality in septic patients, as was SOFA score. They reported that the area under the curve (AUC) of OSM for predicting 28-day mortality in septic patients was 0.80 on day of ICU admission which was significantly higher than that of SOFA score (AUC, 0.730) and procalcitonin (AUC, 0.65). The findings were supported in a mouse model. In CLP-induced polymicrobial sepsis, anti-OSM antibody decreased tissue inflammation and injury, and thus improved survival, while local and systemic bacterial dissemination was almost constant.

The authors concluded that their pilot study found a significant elevation in the serum OSM levels in the patients with sepsis, and OSM levels correlated with disease severity of sepsis. Moreover, the serum OSM level on day of ICU admission was related to 28-day mortality in septic patients. These results suggest that OSM measurement may represent a new biomarker for identification of a group of septic patients presenting with higher risk of mortality. The study was published on January 13, 2020 in the Journal of Infectious Diseases.

Related Links:
Chongqing Medical University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more